With Manipal Hospital Enterprise getting the go-ahead from Fortis Healthcare’s Board to take over the latter’s hospitals, here’s a list of major mergers and acquisitions in the pharmaceuticals sector.
As Fortis Healthcare’s Board has approved the de-merger of its hospitals business to Manipal Hospital Enterprises, Dr Ranjan Pai and TPG are expected to invest a whopping Rs 3,900 crore in Manipal Hospitals.
Here’s a list of major mergers and acquisitions (M&As) in the pharmaceuticals sector:
Sun Pharma-Ranbaxy merger: In a USD 4 billion deal, Sun Pharma is on track to unlock synergies of USD 300 million by merging Ranbaxy by end-FY18.
Sun Pharma-Taro acquisition: In September 2010, the Mumbai-headquartered company acquired the US-based pharma firm in a USD 273 million deal. Taro has been one of Sun’s most lucrative acquisitions, with payback within 3 years and return-of-capital of 641 percent according to moneycontrol.com.
Torrent Pharma-Elder portfolio acquisition: In a USD 323 million deal, Torrent sought to expand its India portfolio and scale up sub-optimal products. The deal was a hit for Torrent with 23 percent CAGR of Elder’s brands over FY14-17.
Jubilant-Draxis acquisition: In April 2008, Jubilant acquired Draxis in a USD 255 million deal. The acquisition was turned profitable from the second year. However, the US launch of Ruby-Fill, expected in 2010 at the time of acquisition, was delayed and the product was eventually launched in 2017.
Aurobindo Pharma-Natrol acquisition: To foray into nutraceuticals in the US, the Hyderabad-headquartered firm acquired Natrol in a USD 132.5 million deal.
Aurobindo Pharma – Actavis Western Europe biz acquisition: In 2014, Aurobindo took over Actavis in a EUR 30 million deal to expand its presence and portfolio in Europe.
Abbott-Piramal acquisition: Deal size – USD 3.7 billion.
Lupin-Gavis acquisition: Deal size – USD 880 million.
Cipla-InvaGen/Exelan acquisition: Deal size – USD 550 million.
Here are some M&As that are in progress:
Dr Reddy’s-Teva (8 ANDAs/generic filings): Deal size – USD 350 million.
Strides Arcolab-Shasun merger: Deal size – USD 323 million.
Piramal-Mallinckrodt: Deal size – USD 273 million
Dr Reddy’s – Betapharm acquisition: Deal size – USD 571 million.
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…